Skip to main content
Erschienen in: Der Nephrologe 1/2013

01.01.2013 | Leitthema

Phosphatbinder

verfasst von: Prof. M. Ketteler

Erschienen in: Die Nephrologie | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hyperphosphatämie ist ein typischer Befund im Endstadium chronischer Nierenerkrankungen („chronic kidney disease“, CKD). Präklinische und Beobachtungsstudien weisen überzeugend und nachdrücklich darauf hin, dass die Hyperphosphatämie unmittelbar pathogenetisch bedeutsam ist für kardiovaskuläre Komplikationen, insbesondere für das Auftreten progressiver Gefäß- und Weichteilverkalkungen, sowie für die Gesamt- und die kardiovaskuläre Mortalität dieser Population. Insofern spielt das adäquate Management des Phosphathaushalts derzeit eine zentrale Rolle bei der Behandlung von CKD-Patienten. Neben diätetischer Phosphatrestriktion und Modifikationen des Dialyseregimes kommen hier in erster Linie Phosphatbinder zum Einsatz. Diese Übersichtsarbeit fokussiert auf die Therapierationale der Hyperphosphatämie, auf die Stärken und Limitationen der verfügbaren Phosphatbinder, auf neue Erkenntnisse zur Phosphatregulation und auf deren Konsequenzen für zukünftige Therapiestrategien sowie auf potenziell neue Behandlungsansätze.
Literatur
1.
Zurück zum Zitat Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8:117PubMedCrossRef Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8:117PubMedCrossRef
2.
Zurück zum Zitat Couser WG, Remuzzi G, Mendis S, Tonelli M (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258–1270PubMedCrossRef Couser WG, Remuzzi G, Mendis S, Tonelli M (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258–1270PubMedCrossRef
3.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl 76(Suppl 113):S1–S130 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl 76(Suppl 113):S1–S130
4.
Zurück zum Zitat Giachelli CM (2009) The emerging role of phosphate in vascular calcification. Kidney Int 75:890–897PubMedCrossRef Giachelli CM (2009) The emerging role of phosphate in vascular calcification. Kidney Int 75:890–897PubMedCrossRef
5.
Zurück zum Zitat Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26:1948−1955PubMedCrossRef Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26:1948−1955PubMedCrossRef
6.
Zurück zum Zitat Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519−530PubMedCrossRef Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519−530PubMedCrossRef
7.
Zurück zum Zitat Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607−617PubMedCrossRef Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607−617PubMedCrossRef
8.
Zurück zum Zitat Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JASN 15:2208−2218PubMedCrossRef Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JASN 15:2208−2218PubMedCrossRef
9.
Zurück zum Zitat Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. JASN 16:1788−1793PubMedCrossRef Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. JASN 16:1788−1793PubMedCrossRef
10.
Zurück zum Zitat Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312−1324PubMedCrossRef Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312−1324PubMedCrossRef
11.
Zurück zum Zitat Miyamoto K, Haito-Sugino S, Kuwahara S et al (2011) Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 100:3719−3730PubMedCrossRef Miyamoto K, Haito-Sugino S, Kuwahara S et al (2011) Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 100:3719−3730PubMedCrossRef
12.
Zurück zum Zitat Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. JASN 20:1453−1464PubMedCrossRef Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. JASN 20:1453−1464PubMedCrossRef
13.
Zurück zum Zitat Sigrist MK, Taal MW, Bungay P, McIntyre CW (2007) Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. CJASN 2:1241–1248PubMed Sigrist MK, Taal MW, Bungay P, McIntyre CW (2007) Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. CJASN 2:1241–1248PubMed
14.
Zurück zum Zitat Block GA, Wheeler DC, Persky MS et al (2012) Effects of phosphate binders in moderate CKD. JASN 23:1407–1415PubMedCrossRef Block GA, Wheeler DC, Persky MS et al (2012) Effects of phosphate binders in moderate CKD. JASN 23:1407–1415PubMedCrossRef
15.
Zurück zum Zitat Russo D, Miranda I, Ruocco C et al (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72:1255–1261PubMedCrossRef Russo D, Miranda I, Ruocco C et al (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72:1255–1261PubMedCrossRef
16.
Zurück zum Zitat KDOQI, National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(Suppl 3):S11–S145CrossRef KDOQI, National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(Suppl 3):S11–S145CrossRef
17.
Zurück zum Zitat Heng A-E, Cano NJM (2010) Nutritional problems in adult patients with stage 5 chronic kidney disease on dialysis (both haemodialysis and peritoneal dialysis). Nephrol Dial Transplant Plus 3:109–117, 118 Heng A-E, Cano NJM (2010) Nutritional problems in adult patients with stage 5 chronic kidney disease on dialysis (both haemodialysis and peritoneal dialysis). Nephrol Dial Transplant Plus 3:109–117, 118
18.
Zurück zum Zitat Noori N, Kalantar-Zadeh K, Kovesdy CP et al (2010) Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. CJASN 5:683–692PubMed Noori N, Kalantar-Zadeh K, Kovesdy CP et al (2010) Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. CJASN 5:683–692PubMed
19.
Zurück zum Zitat Shinaberger CS, Greenland S, Kopple JD et al (2008) Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88:1511–1518PubMedCrossRef Shinaberger CS, Greenland S, Kopple JD et al (2008) Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88:1511–1518PubMedCrossRef
20.
Zurück zum Zitat Lynch KE, Lynch R, Curhan GC, Brunelli SM (2011) Prescribed dietary phosphate restriction and survival among hemodialysis patients. CJASN 6:620–629PubMed Lynch KE, Lynch R, Curhan GC, Brunelli SM (2011) Prescribed dietary phosphate restriction and survival among hemodialysis patients. CJASN 6:620–629PubMed
21.
Zurück zum Zitat Sullivan C, Sayre SS, Leon JB et al (2009) Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 301:629–635PubMedCrossRef Sullivan C, Sayre SS, Leon JB et al (2009) Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 301:629–635PubMedCrossRef
22.
Zurück zum Zitat Isakova T, Gutiérrez OM, Chang Y et al (2009) Phosphorus binders and survival on hemodialysis. JASN 20:388–396PubMedCrossRef Isakova T, Gutiérrez OM, Chang Y et al (2009) Phosphorus binders and survival on hemodialysis. JASN 20:388–396PubMedCrossRef
23.
Zurück zum Zitat Cannata-Andia JB (2012) The use of phosphate binding agents is associated with lower mortality: results from the COSMOS study. 49th ERA-EDTA Congress, May 24–27, 2012, Paris Cannata-Andia JB (2012) The use of phosphate binding agents is associated with lower mortality: results from the COSMOS study. 49th ERA-EDTA Congress, May 24–27, 2012, Paris
24.
Zurück zum Zitat Lopes AA, Tong L, Thumma J et al (2012) Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60:90–101PubMedCrossRef Lopes AA, Tong L, Thumma J et al (2012) Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60:90–101PubMedCrossRef
25.
Zurück zum Zitat Qunibi WY, Hootkins RE, McDowell LL et al (2004) Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914–1926PubMedCrossRef Qunibi WY, Hootkins RE, McDowell LL et al (2004) Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914–1926PubMedCrossRef
26.
Zurück zum Zitat Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF (2006) Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology (Carlton) 11:142–146 Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF (2006) Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology (Carlton) 11:142–146
27.
Zurück zum Zitat Jean G, Lataillade D, Genet L et al (2011) Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 15:485–492PubMedCrossRef Jean G, Lataillade D, Genet L et al (2011) Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 15:485–492PubMedCrossRef
28.
Zurück zum Zitat Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRef Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRef
29.
Zurück zum Zitat Francisco AL de, Leidig M, Covic AC et al (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25:3707–3717PubMedCrossRef Francisco AL de, Leidig M, Covic AC et al (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25:3707–3717PubMedCrossRef
31.
Zurück zum Zitat De Santo NG, Frangiosa A, Anastasio P et al (2006) Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 19(Suppl 9):S108–S114 De Santo NG, Frangiosa A, Anastasio P et al (2006) Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 19(Suppl 9):S108–S114
32.
Zurück zum Zitat Delmez J, Block G, Robertson J et al (2007) A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 68:386–391PubMed Delmez J, Block G, Robertson J et al (2007) A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 68:386–391PubMed
33.
Zurück zum Zitat Pai AB, Shepler BM (2009) Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 29:554–561PubMedCrossRef Pai AB, Shepler BM (2009) Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 29:554–561PubMedCrossRef
34.
Zurück zum Zitat Suki WN, Zabaneh R, Cangiano JL et al (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137PubMedCrossRef Suki WN, Zabaneh R, Cangiano JL et al (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137PubMedCrossRef
35.
Zurück zum Zitat Di Iorio B, Bellasi A, Russo D; IDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. CJASN 7:487–493 Di Iorio B, Bellasi A, Russo D; IDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. CJASN 7:487–493
36.
Zurück zum Zitat Block GA, Spiegel DM, Ehrlich J et al (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815–1824PubMedCrossRef Block GA, Spiegel DM, Ehrlich J et al (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815–1824PubMedCrossRef
37.
Zurück zum Zitat Braun J, Asmus HG, Holzer H et al (2004) Long-term comparison of a calcium-free phosphate binder and calcium carbonate – phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62:104–115PubMed Braun J, Asmus HG, Holzer H et al (2004) Long-term comparison of a calcium-free phosphate binder and calcium carbonate – phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62:104–115PubMed
38.
Zurück zum Zitat Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252PubMedCrossRef Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252PubMedCrossRef
39.
Zurück zum Zitat Qunibi W, Moustafa M, Muenz LR et al (2008) A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51:952–965PubMedCrossRef Qunibi W, Moustafa M, Muenz LR et al (2008) A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51:952–965PubMedCrossRef
40.
Zurück zum Zitat Zhang Q, Li M, Lu Y et al (2010) Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 115:c259–c267PubMedCrossRef Zhang Q, Li M, Lu Y et al (2010) Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 115:c259–c267PubMedCrossRef
41.
Zurück zum Zitat Brandenburg VM, Schlieper G, Heussen N et al (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 25:2672–2679PubMedCrossRef Brandenburg VM, Schlieper G, Heussen N et al (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 25:2672–2679PubMedCrossRef
42.
Zurück zum Zitat Finn WF, SPD 405–307 Lanthanum Study Group (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65:191–202PubMed Finn WF, SPD 405–307 Lanthanum Study Group (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65:191–202PubMed
43.
Zurück zum Zitat Sprague SM, Ross EA, Nath SD et al (2009) Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 72:252–258PubMed Sprague SM, Ross EA, Nath SD et al (2009) Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 72:252–258PubMed
44.
Zurück zum Zitat Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 26:2567–2571PubMedCrossRef Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 26:2567–2571PubMedCrossRef
45.
Zurück zum Zitat D’Haese PC, Spasovski GB, Sikole A et al (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85:S73–S78 D’Haese PC, Spasovski GB, Sikole A et al (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85:S73–S78
46.
Zurück zum Zitat Lacour B, Lucas A, Auchère D et al (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67:1062–1069PubMedCrossRef Lacour B, Lucas A, Auchère D et al (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67:1062–1069PubMedCrossRef
47.
Zurück zum Zitat Hutchison AJ, Barnett ME, Krause R et al (2009) Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 71:286–295PubMed Hutchison AJ, Barnett ME, Krause R et al (2009) Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 71:286–295PubMed
48.
Zurück zum Zitat Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9:2PubMedCrossRef Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9:2PubMedCrossRef
49.
Zurück zum Zitat Chiu YW, Teitelbaum I, Misra M et al (2009) Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. CJASN 4:1089–1096PubMed Chiu YW, Teitelbaum I, Misra M et al (2009) Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. CJASN 4:1089–1096PubMed
50.
Zurück zum Zitat Daugirdas JT, Chertow GM, Larive B et al (2012) Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. JASN 23:727–738PubMedCrossRef Daugirdas JT, Chertow GM, Larive B et al (2012) Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. JASN 23:727–738PubMedCrossRef
51.
Zurück zum Zitat Cheng SC, Young DO, Huang Y et al (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. CJASN 3:1131–1138PubMed Cheng SC, Young DO, Huang Y et al (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. CJASN 3:1131–1138PubMed
52.
Zurück zum Zitat Locatelli F, Dimkovic N, Pontoriero G et al (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 25:574–581PubMedCrossRef Locatelli F, Dimkovic N, Pontoriero G et al (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 25:574–581PubMedCrossRef
53.
Zurück zum Zitat Geisser P, Philipp E (2010) PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74:4–11PubMed Geisser P, Philipp E (2010) PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74:4–11PubMed
54.
Zurück zum Zitat Umanath K, Sika M, Niecestro R et al (2012) Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int [Epub ahead of print] Umanath K, Sika M, Niecestro R et al (2012) Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int [Epub ahead of print]
55.
Zurück zum Zitat Savica V, Calò LA, Monardo P et al (2009) Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. JASN 20:639–644PubMedCrossRef Savica V, Calò LA, Monardo P et al (2009) Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. JASN 20:639–644PubMedCrossRef
Metadaten
Titel
Phosphatbinder
verfasst von
Prof. M. Ketteler
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Die Nephrologie / Ausgabe 1/2013
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI
https://doi.org/10.1007/s11560-012-0650-y

Weitere Artikel der Ausgabe 1/2013

Der Nephrologe 1/2013 Zur Ausgabe

Leitthema

Kalzimimetika

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.